D-1869-2019 Class II Terminated

Recalled by Aurolife Pharma, LLC — Dayton, NJ

FDA drug recall D-1869-2019 was initiated by Aurolife Pharma, LLC on Aug 23, 2019 and is designated Class II. Reason for recall: Failed Impurities/Degradation Specifications The recall status is terminated (terminated Aug 16, 2022). Affected quantity: 129,600 cartons.

Recall Details

Product Type
Drugs
Report Date
Sep 25, 2019
Initiation Date
Aug 23, 2019
Termination Date
Aug 16, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
129,600 cartons

Product Description

Allergy Relief (Fexofenadine HCl) tablets USP, 180 mg, 15-count cartons, equate, Distributed by: Wal-Mart Stores, Inc., Bentonville, AR 72716, NDC 49035-995-62.

Reason for Recall

Failed Impurities/Degradation Specifications

Distribution Pattern

Nationwide in the USA

Code Information

Lot #s: 067180010A, Exp 03/21; 067180023C1, 067180024D1, Exp 07/21

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1869-2019
openFDA file date
Nov 3, 2026
Loaded by RegDataLab
Nov 4, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1869-2019. Report a data issue: hello@regdatalab.com.